A molecular switch in immunodominant HIV-1-specific CD8 T-cell epitopes shapes differential HLA-restricted escape

Retrovirology

Volumn 12, Issue 1, 2015, Pages

  Kløverpris, Henrik N ^a,e,f   Cole, David K ^b   Fuller, Anna ^b   Carlson, Jonathan ^c   Beck, Konrad ^d   Schauenburg, Andrea J ^d   Rizkallah, Pierre J ^d   Buus, Søren ^e   Sewell, Andrew K ^b   Goulder, Philip ^f  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^c MICROSOFT RESEARCH   (United States)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

HIV 1*CD8+ T Cells; pHLA structure; Viral escape

Indexed keywords

EPITOPE; GAG PROTEIN; GAG PROTEIN (180-188); HLA ANTIGEN CLASS 1; HLA B ANTIGEN; NEF PROTEIN; NEF PROTEIN (71-79); UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN;

ADULT; ARTICLE; BACTERIAL CELL; CD8+ T LYMPHOCYTE; CELL SHAPE; CONFORMATIONAL TRANSITION; DISEASE COURSE; ESCHERICHIA COLI; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE EVASION; MOLECULAR STABILITY; NONHUMAN; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PURIFICATION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURE ANALYSIS; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HIV ANTIGENS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNE EVASION;

EID: 84924198550     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/s12977-015-0149-5     Document Type: Article

References (30)

1. Trowsdale J. HLA genomics in the third millennium. Curr Opin Immunol. 2005;17:498-504.
2. Garboczi DN, Ghosh P, Utz U, Fan QR, Biddison WE, Wiley DC. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature. 1996;384:134-41.
3. Gao X, Nelson GW, Karacki P, Martin MP, Phair J, Kaslow R, et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med. 2001;344:1668-75.
4. Geldmacher C, Metzler IS, Tovanabutra S, Asher TE, Gostick E, Ambrozak DR, et al. Minor viral and host genetic polymorphisms can dramatically impact the biologic outcome of an epitope-specific CD8 T-cell response. Blood. 2009;114:1553-62.
5. Goulder PJ, Walker BD. HIV and HLA class I: an evolving relationship. Immunity. 2012;37:426-40.
6. Jin X, Gao X, Ramanathan Jr M, Deschenes GR, Nelson GW, O'Brien SJ, et al. Human immunodeficiency virus type 1 (HIV-1)-specific CD8 + -T-cell responses for groups of HIV-1-infected individuals with different HLA-B*35 genotypes. J Virol. 2002;76:12603-10.
7. Kloverpris HN, Harndahl M, Leslie AJ, Carlson JM, Ismail N, van der Stok M, et al. HIV control through a single nucleotide on the HLA-B locus. J Virol. 2012;86:11493-500.
8. Kloverpris HN, Stryhn A, Harndahl M, van der Stok M, Payne RP, Matthews PC, et al. HLA-B*57 micropolymorphism shapes HLA allele-specific epitope immunogenicity, selection pressure, and HIV immune control. J Virol. 2012;86:919-29.
9. Carlson JM, Listgarten J, Pfeifer N, Tan V, Kadie C, Walker BD, et al. Widespread impact of HLA restriction on immune control and escape pathways of HIV-1. J Virol. 2012;86:5230-43.
10. Matthews PC, Prendergast A, Leslie A, Crawford H, Payne R, Rousseau C, et al. Central role of reverting mutations in HLA associations with human immunodeficiency virus set point. J Virol. 2008;82:8548-59.
11. Goulder PJ, Brander C, Annamalai K, Mngqundaniso N, Govender U, Tang Y, et al. Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected African and caucasoid adults and children. J Virol. 2000;74:5679-90.
12. Honeyborne I, Rathod A, Buchli R, Ramduth D, Moodley E, Rathnavalu P, et al. Motif inference reveals optimal CTL epitopes presented by HLA class I alleles highly prevalent in southern Africa. J Immunol. 2006;176:4699-705.
13. Wright JK, Naidoo VL, Brumme ZL, Prince JL, Claiborne DT, Goulder PJ, et al. Impact of HLA-B*81-associated mutations in HIV-1 Gag on viral replication capacity. J Virol. 2012;86:3193-9.
14. Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, Chetty S, et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature. 2004;432:769-75.
15. Prentice HA, Porter TR, Price MA, Cormier E, He D, Farmer PK, et al. HLA-B*81 in HIV-1 infection: slow and steady wins the race? J Virol. 2013;87:4043-51.
16. Leslie A, Matthews PC, Listgarten J, Carlson JM, Kadie C, Ndung'u T, et al. Additive contribution of HLA class I alleles in the immune control of HIV-1 infection. J Virol. 2010;84:9879-88.
17. Leslie A, Price DA, Mkhize P, Bishop K, Rathod A, Day C, et al. Differential selection pressure exerted on HIV by CTL targeting identical epitopes but restricted by distinct HLA alleles from the same HLA supertype. J Immunol. 2006;177:4699-708.
18. Kloverpris HN, Adland E, Koyanagi M, Stryhn A, Harndahl M, Matthews PC, et al. HIV subtype influences HLA-B*07:02-associated HIV disease outcome. AIDS Res Hum Retroviruses. 2014;30:468-75.
19. Tickle IJ, Laskowski RA, Moss DS. Rfree and the rfree ratio. II. Calculation of the expected values and variances of cross-validation statistics in macromolecular least-squares refinement. Acta Crystallogr D Biol Crystallogr. 2000;56:442-50.
20. Cole DK, Yuan F, Rizkallah PJ, Miles JJ, Gostick E, Price DA, et al. Germ line-governed recognition of a cancer epitope by an immunodominant human T-cell receptor. J Biol Chem. 2009;284:27281-9.
21. Payne RP, Kloverpris H, Sacha JB, Brumme Z, Brumme C, Buus S, et al. Efficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B*57.
22. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med. 2007;13:46-53.
23. Harndahl M, Rasmussen M, Roder G, Buus S. Real-time, high-throughput measurements of peptide-MHC-I dissociation using a scintillation proximity assay. J Immunol Methods. 2011;374(1-2):5-12.
24. Greenfield NJ. Analysis of circular dichroism data. Methods Enzymol. 2004;383:282-317.
25. Venyaminov S, Baikalov IA, Shen ZM, Wu CS, Yang JT. Circular dichroic analysis of denatured proteins: inclusion of denatured proteins in the reference set. Anal Biochem. 1993;214:17-24.
26. Cole DK, Dunn SM, Sami M, Boulter JM, Jakobsen BK, Sewell AK. T cell receptor engagement of peptide-major histocompatibility complex class I does not modify CD8 binding. Mol Immunol. 2008;45:2700-9.
27. Cole DK, Rizkallah PJ, Gao F, Watson NI, Boulter JM, Bell JI, et al. Crystal structure of HLA-B*2402 complexed with a telomerase peptide. Eur J Immunol. 2006;36:170-9.
28. Bulek AM, Madura F, Fuller A, Holland CJ, Schauenburg AJ, Sewell AK, et al. TCR/pMHC optimized protein crystallization screen. J Immunol Methods. 2012;382:203-10.
29. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. J Appl Crystallogr. 2007;40:658-74.
30. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004;60:2126-32.